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may effectively inhibit multiple areas of neuronal 
excitability (20).
In this study the spinal fluid and blood concentrations 
of fentanyl were not measured. It seems that 
it is advantageous to measure onset time of 
block objectively, with computer–assisted infrared 
thermography camera. Further work is required to 
define the role of peripherally acting opioids in this 
situation.  
CONCLUSION
From the results of this study , it appears that addition 
Fentanyl supplement expedites…
of 75 µg fentanyl to 1.5% lidocaine solution shorten 
the onset times of sensory and motor blocks during 
the interscalene brachial plexus block without any 
increase in side effects.
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ABSTRACT
Background and the purpose of the study: Experimental and preclinical observations have 
indicated that combination therapy with all-trans-retinoic acid (ATRA) and arsenic trioxide 
(ATO) may strongly enhance their therapeutic effects in the treatment of acute promyelocytic 
leukemia  (APL).  Whilst  dexamethasone  (Dex)  is  routinely  used  for  the  control  of APL-
differentiation syndrome, its effect on the pharmacodynamics of ATO is not clear. Therefore, 
in this study, effects of therapeutic concentrations of ATO, ATRA and Dex and their sequential 
usages on the proliferation, differentiation and apoptosis in t(15;17)-positive NB4 cells was 
investigated.
Methods: Cells were treated with therapeutic concentrations of ATO, ATRA and Dex either 
as single or in combination and cell proliferation was assessed by XTT assay. Expression of 
CD11b as an indicator of cell differentiation and the percentage of 7-AAD positive cells as a 
marker of apoptosis were determined by flow cytometry.
Results: ATO, but not ATRA and Dex, decreased proliferation of the cells dose-dependently. 
Pre-treatment of the cells with any of the drugs did not alter the effects of other drugs on the 
proliferation. Pre-treatments with Dex blocked the apoptotic effect of ATO (1 µM). 
Conclusion: N o  improvement  or  antagonistic  effects  was  observed  with  the  pretreatment/
combination of the ATO and ATRA on the differentiation and apoptosis of the cells. It is 
possible that concomitant usage of Dex with apoptotic doses of ATO in APL patients counteract 
therapeutic effects of ATO.
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DARU Vol. 18, No. 4 2010
Correspondence: alimandegary@kmu.ac.ir
INTRODUCTION
Acute  myeloid  leukemia  (AML)  is  a  disease 
characterised by abnormalities in the proliferation/
differentiation  coupling.  The  exact  cause  of 
leukemia is not yet well known; however, family 
history, smoking, long term exposure to chemicals 
such as benzene, prolonged exposure to radiation 
(1)  and  abnormalities  in  the  processes  of  cell 
proliferation,  differentiation  and  apoptosis  (2-
4)  have  been  mentioned  for  this  disease.  Acute 
promyelocytic  leukemia  (APL)  is  a  well-defined 
subtype of leukemia which accounts for 10-15% of 
acute myeloid leukemias. The APL is characterized 
by  PML/RARα  fusion  protein  resulting  from  a 
reciprocal  translocation  between  the  retinoic  acid 
receptor-α (RARα) gene on the chromosome 17 and 
the PML gene on the chromosome 15. The PML/
RARα is leukemogenic and blocks the differentiation 
and apoptosis of promyelocytes. All-trans retinoic 
acid (ATRA) has therapeutic effect in APL due to its 
capability to induce the differentiation of leukaemia 
cells into mature granulocytes. 
Recently, arsenic trioxide (ATO) has been used to 
treat relapsed and newly diagnosed APL patients (5, 
6). At the molecular level, ATO exerts a number of 
dose-dependent dual effects on APL cells such as 
induction  of  apoptosis  and  partial  differentiation 
at  concentrations  of  0.5-2.0  µM  and  0.1-0.5  µM, 
respectively (7). Recently we have shown the role of 
Bax, p38 and ERK1 proteins in differentiation and 
apoptosis of promyelocytes in APL patients during 
treatment  with  ATO  (6).  There  are  controversial 
in  vivo  and  in  vitro  reports  on  the  preference  of 
ATRA/ATO combination therapy for APL and non-
APL over monotherapy with each of them (5, 8-10). 
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pre-treatment and combination therapy of ATO and 
ATRA (8, 11). 
APL-differentiation syndrome is a life threatening 
adverse effect of differentiating agents like ATO and 
ATRA used for the treatment of APL. Administration 
of  high  doses  of  corticosteroids  especially  Dex 
have  proved  to  be  very  effective  treatment  for 
prevention of this syndrome (6, 12). Highdoses of 
methylprednisolone  has  been  shown  to  induce  in 
vivo and in vitro differentiation of myeloid leukemia 
cells to mature granulocytes in patients with APL and 
other subtypes of AML (13). However, an important 
question is whether the prophylactic and concomitant 
corticosteroid treatment could potentially affect the 
efficacy  and  potency  of ATO  and ATRA  therapy. 
This study was undertaken to delineate the possible 
interferences  of  Dex  with  the  therapeutic  actions 
of ATO and ATRA to address the aforementioned 
question.
In this study effects of pre-treatment with ATRA 
and  Dex  on  ATO-induced  apoptosis,  effects  of 
Dex  on  ATO  and  ATRA-induced  differentiation 
and  effects  of  combination  of  these  drugs  on 
proliferation and/or toxicity of NB4-APL cell line 
were investigated.  
MATERIAL AND METHODS
Reagents 
Arsenic trioxide (As2O3; ATO) was purchased from 
Sigma  Chemical  Co  (St  Louis,  MO,  USA)  and 
dissolved in NaOH alkalinized deionized water in 
the  stock  concentration  of  1  M  and  then  diluted 
with PBS to a working concentration of 50 µM. All-
trans retinoic acid was purchased from Sigma and 
dissolved in 100% ethanol to a stock concentration 
of 1 M, stored light protected at -20°C. For every 
experiment the fresh working solution of 500 µM 
of ATRA was prepared in absolute ethanol. Water 
soluble Dex (Dexamethasone dihydrogenphosphate; 
Dexa-rattiopharm®,  Germany)  was  diluted  to 
working solution of 500 µM with phosphate-buffered 
saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, pH of 7.4).
Cell culture
The NB4 promyelocytic cell line was maintained in 
complete medium containing RPMI 1640 medium 
(Sigma,  USA)  with  10%  FBS  (Gibco,  USA),                       
100  U/ml  penicillin  and  100  mg/ml  streptomycin 
(Gibco, USA) in a humidified atmosphere with 5% 
CO2  at  the  concentration  of  1×105/ml  -  1×106/ml 
cells.
Pre-treatment and treatment of cells
For  pre-treatment,  cells  were  cultured  in  four 
groups  using  complete  medium  in  25  cm2  tissue 
culture flasks. The first group was pre-treated with 
ATO (0.25 µM), the second with ATRA (1 µM), the 
third with Dex (1 µM) and the forth with no pre-
treatment. After  24  hrs,  all  groups  of  cells  were 
washed  with  PBS  and  re-suspended  in  complete 
medium  containing  the  same  reagents  as  above. 
Then, all cells were subjected to further treatments 
as follows: Group 1 was divided in three subgroups 
receiving ATRA (0.5 and 1 μM respectively) and 1 
μM of Dex; group 2 was divided in three subgroups 
receiving ATO (0.25 and 1 μM respectively) and 1 
μM of Dex; three subgroups of group 3 received ATO 
(0.25 and 1 μM) and 1 μM of ATRA respectively. 
Group 4 was divided in four subgroups receiving 
ATRA (0.5 and 1 μM respectively), 0.25 μM of ATO 
and 1 μM of Dex.
In co-treatment experiments, each of the four main 
groups of cells were each treated for 24 hrs with 
one main drug and various concentrations of other 
drug partners as outlined in the legends of respective 
graphs. 
XTT assay for cellular proliferation
Aliquots of 100 µl of the cell suspension containing 
30,000  cells  were  dispensed  into  96-well  flat-
bottomed microplates. The proliferation of the cells 
was assessed using XTT Cell Proliferation Kit II 
(Roche, Germany) according to the manufacturer’s 
guideline.  Eexperiments  were  performed  in 
triplicates and repeated three times. Absorbance at 
450 nm (A450nm) of the formazan was measured using 
a microplate reader adjusted to zero by the reagent 
blanks  to  correlate  the  colored  product  with  the 
number of cells, and the results were expressed as a 
ratio of the treated cells over the untreated cells.
Flow cytometric analysis of differentiation
Cells  were  incubated  for  30  min  with  PE-
conjugated  mouse  anti-human  CD11b  antibody 
(Becton  Dickinson,  USA).  Control  studies  were 
performed with non-binding control mouse IgG2a 
isotype antibodies (Becton Dickinson, USA). The 
percentage of CD11b positive cells was determined 
by measurement of the fluorescence intensity using 
FAC Scan (Becton Dickinson, USA)
Apoptosis assay
For  staining  of  apoptotic  and  dead  cells,  the  7-
amino-actinomycin  D  (7-AAD)  method  was  used 
(14). Briefly, after culture of NB4 cells to 24-well 
plate, the cells were incubated with ATO (0.25 µM), 
ATRA (1 µM) or Dex (1µM). After 24 hrs incubation 
in a CO2 incubator, the second drug (ATO, ATRA or 
Dex) was added to the corresponding well, then after 
6, 12 and 24 hrs an aliquot of cells was harvested 
by  centrifugation  and  incubated with  20 µg  of  7-
AAD per ml in PBS containing 2% calf serum and 
0.1% sodium azide (Sigma, USA) (PBSAz) and in 
the absence of Ca2+ and Mg2+, for 20 min at 4°C 
protected from light. The cells were then analyzed 
on a FACScan flow cytometer (Becton Dickinson) in 305 Effects of combination of arsenic trioxide and all-trans-retinoic acid and dexamethasone
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APL-differentiation syndrome is a life threatening 
adverse effect of differentiating agents like ATO and 
ATRA used for the treatment of APL. Administration 
of  high  doses  of  corticosteroids  especially  Dex 
have  proved  to  be  very  effective  treatment  for 
prevention of this syndrome (6, 12). Highdoses of 
methylprednisolone  has  been  shown  to  induce  in 
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the  stock  concentration  of  1  M  and  then  diluted 
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μM of Dex; group 2 was divided in three subgroups 
receiving ATO (0.25 and 1 μM respectively) and 1 
μM of Dex; three subgroups of group 3 received ATO 
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Group 4 was divided in four subgroups receiving 
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ratio of the treated cells over the untreated cells.
Flow cytometric analysis of differentiation
Cells  were  incubated  for  30  min  with  PE-
conjugated  mouse  anti-human  CD11b  antibody 
(Becton  Dickinson,  USA).  Control  studies  were 
performed with non-binding control mouse IgG2a 
isotype antibodies (Becton Dickinson, USA). The 
percentage of CD11b positive cells was determined 
by measurement of the fluorescence intensity using 
FAC Scan (Becton Dickinson, USA)
Apoptosis assay
For  staining  of  apoptotic  and  dead  cells,  the  7-
amino-actinomycin  D  (7-AAD)  method  was  used 
(14). Briefly, after culture of NB4 cells to 24-well 
plate, the cells were incubated with ATO (0.25 µM), 
ATRA (1 µM) or Dex (1µM). After 24 hrs incubation 
in a CO2 incubator, the second drug (ATO, ATRA or 
Dex) was added to the corresponding well, then after 
6, 12 and 24 hrs an aliquot of cells was harvested 
by  centrifugation  and  incubated with  20 µg  of  7-
AAD per ml in PBS containing 2% calf serum and 
0.1% sodium azide (Sigma, USA) (PBSAz) and in 
the absence of Ca2+ and Mg2+, for 20 min at 4°C 
protected from light. The cells were then analyzed 
on a FACScan flow cytometer (Becton Dickinson) in 
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Dex (1 μM) (Figure 1). Combined treatment of Dex with 1μM of ATO counteracted the 
antiproliferative effect of ATO, but not significantly. 
 
Figure 1. Proliferation of NB4 cells in response to therapeutic concentrations of ATO, ATRA 
and Dex alone or in combination. Cell proliferation was assessed by XTT assay for cellular 
proliferation. *** p< 0.001 compared to NB4 without any treatment, 
¶¶¶ p<0.001 compared to 
ATRA at 0.5 μM, 
§ p<0.05 and 
§§§ p<0.001 compared to ATRA at 1μM and †† p>0.01 
compared to Dex. at 1μM, One-way ANOVA.
Effect of pre-treatment of NB4 cells with ATO on the anti-proliferation of cells by ATRA 
and Dex 
Figure 2 shows that the antiproliferative profile of ATRA (0.5 and 1 μM) and Dex (1 
μM) didn’t change when the NB4 cells were pre-treated with low concentration of ATO 
(0.25 μM). 
Figure 1. Proliferation of NB4 cells in response to therapeutic concentrations of ATO, ATRA and Dex alone or in combination. Cell 
proliferation was assessed by XTT assay for cellular proliferation. *** p< 0.001 compared to NB4 without any treatment, ¶¶¶ p<0.001 





Figure 2. Proliferation of pre-treated NB4 cells with 0.25 μM of ATO in response to therapeutic 
concentrations of ATRA and Dex. The cells were pre-treated with 0.25 μM of ATO for 24hrs 
and then second drugs namely ATRA and Dex were added to cells. Normal NB4 cells weren’t 
pre-treated with ATO.  
Effect of Dex pre-treatment on the anti-proliferation of cells by ATO  
Pre-teatment of NB4 cells with 1μM of ATRA did not change the anti-proliferative 
effects of ATO ( 0.25 and 1μM) and 1μM of Dex (Fig 3). Pre-treatment with 1μM of 
Dex also didn’t change the anti-proliferative effect of ATO and ATRA at concentration 
of 1μM (Fig 3).  
 
Figure 3. Effect of ATRA and Dex pre-treatment on the proliferation of NB4 cells in response 
to ATO, ATRA and Dex. NB4 cells pre-incubated with ATRA (1μM) and 1μM Dex 24hrs 
before addition of the second drug. Cell proliferation was assessed by XTT assay for cellular 
Figure 2. Proliferation of pre-treated NB4 cells with 0.25 μM of ATO in response to therapeutic concentrations of ATRA and Dex. The 
cells were pre-treated with 0.25 μM of ATO for 24 hrs and then second drugs namely ATRA and Dex were added to cells. Normal NB4 




Figure 2. Proliferation of pre-treated NB4 cells with 0.25 μM of ATO in response to therapeutic 
concentrations of ATRA and Dex. The cells were pre-treated with 0.25 μM of ATO for 24hrs 
and then second drugs namely ATRA and Dex were added to cells. Normal NB4 cells weren’t 
pre-treated with ATO.  
Effect of Dex pre-treatment on the anti-proliferation of cells by ATO  
Pre-teatment of NB4 cells with 1μM of ATRA did not change the anti-proliferative 
effects of ATO ( 0.25 and 1μM) and 1μM of Dex (Fig 3). Pre-treatment with 1μM of 
Dex also didn’t change the anti-proliferative effect of ATO and ATRA at concentration 
of 1μM (Fig 3).  
 
Figure 3. Effect of ATRA and Dex pre-treatment on the proliferation of NB4 cells in response 
to ATO, ATRA and Dex. NB4 cells pre-incubated with ATRA (1μM) and 1μM Dex 24hrs 
before addition of the second drug. Cell proliferation was assessed by XTT assay for cellular 
Figure 3. Effect of ATRA and Dex pre-treatment on the proliferation of NB4 cells in response to ATO, ATRA and Dex. NB4 cells pre-
incubated with ATRA (1 µM) and 1 µM Dex 24 hrs before addition of the second drug. Cell proliferation was assessed by XTT assay for 
cellular proliferation. *** p< 0.001 compared to normal NB4 and ¶ p<0.05 , ¶¶ p<0.01 compared to ATRA pre-treated cells and † p<0.05 
compared to Dex. Pre-treated cells, One-way ANOVA.306 Effects of combination of arsenic trioxide and all-trans-retinoic acid and dexamethasone
the manufacturer’s staining solution. All data were 
collected, stored and analyzed by Lysis II software 
(Becton Dickinson, USA). 
Statistical analyses
Data were expressed as Means ± SEM of percentage 
of control. One-way analysis of variance (ANOVA) 
followed  by  the  Tukey  HSD  was  used  to  assess 
significant  differences  between  treatment  groups. 
Differences  were  considered  as  significant  when 
p<0.05. 
RESULTS
Effects of ATO, ATRA and Dex on proliferation of 
NB4 cells 
ATO  decreased  the  proliferation  of  NB4  cells 
significantly  (p<0.001)  at  the  concentration  of                     
1 µM. In contrast, ATRA (0.5 and 1 µM) and Dex                                     
(1 µM) only increased the proliferation of NB4 cells 
insignificantly.
Effects of combination treatment with ATRA and Dex 
on the antiproliferative activity of ATO 
The  antiproliferative  profile  of  ATO  in 
concentrations of 0.25 and 0.5 μM was not changed 
when  ATO  used  with  therapeutic  concentrations 
of ATRA (0.5 and 1 μM) and Dex (1 μM)   (Fig 1). 
Combined  treatment  of  Dex  with  1  μM  of ATO 
counteracted the antiproliferative effect of ATO, but 
not significantly.
Effects of pre-treatment of NB4 cells with ATO on 
the anti-proliferation of cells by ATRA and Dex
Figure  2  shows  that  the  antiproliferative  profile 
of ATRA (0.5 and 1 μM) and Dex (1 μM) didn’t 
change when the NB4 cells were pre-treated with 
low concentration of ATO (0.25 μM).
Effects of Dex pre-treatment on the anti-proliferation 
of cells by ATO 
Pre-teatment of NB4 cells with 1 µM of ATRA did 
not  change  the  anti-proliferative  effects  of  ATO 
(0.25 and 1 µM) and 1 µM of Dex (Fig 3). Pre-
treatment  with  1  µM  of  Dex  also  didn’t  change 
the anti-proliferative effects of ATO and ATRA at 
concentration of 1 µM (Fig 3). 
Effects of Dex on differentiation of NB4 cells by 
ATRA 
Pre-treatment  with  ATO  at  0.25  µM  induced 
differentiation  to  nearly  25%  in  NB4  cells 
as  measured  by  expression  of  the  CD11b 
marker.  Addition  of  ATRA  to  the  cells  induced 
CD11b  expression  to 100%  after 24  hrs  but Dex 
insignificantly  decreased  CD11b  expression  (Fig 
4). ATRA induced the expression of CD11b, which 
its pattern of expression was unaffected by ATO or 
Dex. CD11b expression was low (10%) with Dex 
and its presence didn’t counteract CD11b expression 
after addition of ATO and ATRA.
Effects of pre-treatment with Dex on the apoptotic 
effects of ATO and ATRA
NB4 cells were pre-treated with 1 μM of Dex, 0.25 
μM of ATO or 1 μM of ATRA for 24 hrs before 
exposure to 1 μM of ATO or 1 μM of ATRA. The 




Figure 4. Effect of pre-treatment on the CD11b cell-surface expression of NB4 cells after 
exposure to ATO, ATRA and Dex. NB4 cells were treated first with ATO (0.25μM), ATRA 
(1μM) and Dex (1μM) for 24hrs and then second drug was added to cells. (A) Effects of ATRA 
and Dex on the expression of CD11b in the cells pre-treated with ATO. (B) Effects of ATO and 
Dex on the expression of CD11b in the cells pre-treated with ATRA. (C) Effects of ATO and 
ATRA on the expression of CD11b in the cells pre-treated with Dex. Flow-cytometric analysis 
for CD11b cell surface expression was carried out after 6, 12 and 24 hrs. * p< 0.05, ** p< 0.01 
and *** p< 0.001 in comparison to control of each pretreatment using One-Way ANOVA. 
Effect of pre-treatment with Dex on the apoptotic effects of ATO and ATRA 
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the manufacturer’s staining solution. All data were 
collected, stored and analyzed by Lysis II software 
(Becton Dickinson, USA). 
Statistical analyses
Data were expressed as Means ± SEM of percentage 
of control. One-way analysis of variance (ANOVA) 
followed  by  the  Tukey  HSD  was  used  to  assess 
significant  differences  between  treatment  groups. 
Differences  were  considered  as  significant  when 
p<0.05. 
RESULTS
Effects of ATO, ATRA and Dex on proliferation of 
NB4 cells 
ATO  decreased  the  proliferation  of  NB4  cells 
significantly  (p<0.001)  at  the  concentration  of                     
1 µM. In contrast, ATRA (0.5 and 1 µM) and Dex                                     
(1 µM) only increased the proliferation of NB4 cells 
insignificantly.
Effects of combination treatment with ATRA and Dex 
on the antiproliferative activity of ATO 
The  antiproliferative  profile  of  ATO  in 
concentrations of 0.25 and 0.5 μM was not changed 
when  ATO  used  with  therapeutic  concentrations 
of ATRA (0.5 and 1 μM) and Dex (1 μM)   (Fig 1). 
Combined  treatment  of  Dex  with  1  μM  of ATO 
counteracted the antiproliferative effect of ATO, but 
not significantly.
Effects of pre-treatment of NB4 cells with ATO on 
the anti-proliferation of cells by ATRA and Dex
Figure  2  shows  that  the  antiproliferative  profile 
of ATRA (0.5 and 1 μM) and Dex (1 μM) didn’t 
change when the NB4 cells were pre-treated with 
low concentration of ATO (0.25 μM).
Effects of Dex pre-treatment on the anti-proliferation 
of cells by ATO 
Pre-teatment of NB4 cells with 1 µM of ATRA did 
not  change  the  anti-proliferative  effects  of  ATO 
(0.25 and 1 µM) and 1 µM of Dex (Fig 3). Pre-
treatment  with  1  µM  of  Dex  also  didn’t  change 
the anti-proliferative effects of ATO and ATRA at 
concentration of 1 µM (Fig 3). 
Effects of Dex on differentiation of NB4 cells by 
ATRA 
Pre-treatment  with  ATO  at  0.25  µM  induced 
differentiation  to  nearly  25%  in  NB4  cells 
as  measured  by  expression  of  the  CD11b 
marker.  Addition  of  ATRA  to  the  cells  induced 
CD11b  expression  to 100%  after 24  hrs  but Dex 
insignificantly  decreased  CD11b  expression  (Fig 
4). ATRA induced the expression of CD11b, which 
its pattern of expression was unaffected by ATO or 
Dex. CD11b expression was low (10%) with Dex 
and its presence didn’t counteract CD11b expression 
after addition of ATO and ATRA.
Effects of pre-treatment with Dex on the apoptotic 
effects of ATO and ATRA
NB4 cells were pre-treated with 1 μM of Dex, 0.25 
μM of ATO or 1 μM of ATRA for 24 hrs before 
exposure to 1 μM of ATO or 1 μM of ATRA. The 
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counteract the apoptotic effects of ATRA and ATO 
(Fig 5). These effects were even maintained after 
withdrawal  of  each  pre-treatment  (data  are  not 
shown). Meanwhile pre-treatment with ATO did not 
change the apoptotic effect of ATRA and vice versa.
DISCUSSION
There are contradictory reports about the potential 
advantages of ATRA ATO combination therapy for 
APL over monotherapy with each of them (5, 8-10, 
15). Gianni et al (8) have reported that combination 
therapy with ATRA ATO gives better results than 
therapy  with  either  of  the  two  drugs  in  terms  of 
complete  remission  and  status  of  the  disease-
free  survival.  However  ATRA  did  not  improve 
the  response  to ATO  in  relapsed APL  patients  in 
another study (9). Also in agreement with Gianni’s 
report, better  results  for  ATRA/ATO  combination 
therapy than monotherapy has been reported (15). On 
the other hand, Ghavamzadeh et al (5) have shown 
that ATO, with or without ATRA, can yield complete 
remission rate of 86.3% in the newly diagnosed and 
relapsed APL patients. Recently, Ravandi et al (10) 
have concluded that combination of ATO and ATRA 
as first line therapy for APL was effective and safe.
The  finding  that  ATRA  promotes  in  vivo  ATO-
dependent efficacy, prompted us to perform further 
studies to define whether the sequence of these drugs’ 
administration  influence  their  therapeutic  effects, 
namely induction of differentiation and apoptosis. 
In  addition,  the  effect  of  Dex,  which  is  typically 
used to control the symptoms of differentiation of 
APL cells to mature cells, on the effects of ATO and 
ATRA treatment in the NB4 cells were investigated. 
In general aim of this study was to determine if there 
were any effects that could potentially have impact 
on safety and efficacy of this treatment regimen.
Treatment  of  NB4  cells  with  therapeutic 
concentrations of ATO (0.5-1 μM), ATRA (1 μM) 
and Dex (1 μM) for 24 hrs showed that only ATO 
decreased the proliferation of NB4 cells in a dose-
dependent manner leading to significant changes at 
1  μM  concentration.  Conversely, ATRA  and  Dex 
increased the proliferation of cells after 24 hrs to an 
insignificant level (Fig 1).
Results of the evaluation of pre-treatment efficacy 
showed  that  the  proliferation  of  pre-treated  NB4 
cells did not change under the effect of the second 
added drug as compared to unpretreated cells (Figs 
2 and 3). 
It  was  also  investigated  whether  pre-treatment 
with  ATO,  ATRA  and  Dex  would  interfere  with 
differentiation induced by each of them separately. 
ATO at 0.25 μM slightly increased differentiation of 
NB4 cells but did not potentiate the expression of 
CD11b induced by ATRA (Fig 4-A). Dex by itself 
neither induced NB4 cell differentiation nor affected 
the  immunophenotypic  parameter  associated  with 
the  granulocytic  differentiation  induced  by  ATO 
and ATRA (Fig 4-C). This finding does not support 
the  reports  on  the  inductive  effects  of  Dex  on 
differentiation of acute myeloid leukemia and APL 
(16). 
To evaluate the effect of pre-treatment/combination 
therapy on the induction of apoptosis, after treatment 
of cells similar to previous experiments, frequency 
of apoptotic cells were assessed. 
The  observation  that  ATO-induced  apoptosis 
in  NB4  cells  was  not  changed  by  pre-treatment 
with ATRA  (Fig  5)  is  consistent  with  the  result 
of experiments published by Chen et al (17) and 
Gianni  et  al  (8).  However,  Jing  et  al  (11)  have 
shown  that  pre-treatment  with  ATRA  decreased 
ATO-induced  apoptosis  in  ATRA-sensitive  NB4 
but  not  ATRA-resistant  cells.  Notably,  pre-
treatment of cells with Dex significantly decreased 
١٢  
 
treatment with Dex could counteract the apoptotic effects of ATRA and ATO (Fig 5). 
These effects were even maintained after withdrawal of each pretreatment (data are not 
shown). Meanwhile pre-treatment with ATO didn’t change the apoptotic effect of 
ATRA and vice versa. 
 
Figure 5. Effects of pre-treatment of NB4 cells with ATO, ATRA and Dex on apoptotic effects 
of ATO and ATRA. NB4 cells were treated first with ATO (0.25μM), ATRA (1μM) and Dex 
(1μM) for 24hrs. Effects of 1 μM of ATRA on the ATO and Dex pre-treated cells are shown at 
left. The apoptotic effects of ATO at 1 μM on the ATRA and Dex pre-treated cells are shown in 
right. Flow-cytometric analysis for CD11b cell surface expression was carried out after 6 and 24 
hrs. * p< 0.05, ** p< .01 and *** p< 0.001 using One-Way ANOVA. 
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complete remission rate of 86.3% in the newly diagnosed and relapsed APL patients. 
Figure 5. Effects of pre-treatment of NB4 cells with ATO, ATRA and Dex on apoptotic effects of ATO and ATRA. NB4 cells were treated 
with ATO (0.25 µM), ATRA (1 µM) and Dex (1 µM) for 24 hrs. Effects of 1 μM of ATRA on the ATO and Dex pre-treated cells are shown 
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the apoptosis induced by 1 μM of any of ATO and 
ATRA  (Fig  5).  Evidences  demonstrate  that ATO 
and ATRA exert some of their anti-leukemic effects 
through  production  of  reactive  oxygene  species 
(ROS) (18, 19). NADPH oxidase has a major role 
in  arsenic  and  ATRA-induced  reactive  oxygen 
species production, cytotoxicity and maturation of 
APL cells (18, 20). Condino-Neto et al (21) have 
shown that Dex down-regulates the components of 
NADPH oxidase and their activities. Therefore one 
can translate the suppressive effect of Dex on the 
apoptotic effects of ATO and ATRA to the decrease 
in the activity of NADPH oxidase.
Taken  together,  results  of  this  study  showed 
that  pre-treatment  of  NB4  cells  with  therapeutic 
concentrations of ATO and ATRA did not improve 
the  differentiation  and  apoptotic  effects  of  each 
of  them.  Moreover,  using  Dex  with  higher 
concentrations of ATO may counteract therapeutic 
effects of ATO.
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and ATRA exert some of their anti-leukemic effects 
through  production  of  reactive  oxygene  species 
(ROS) (18, 19). NADPH oxidase has a major role 
in  arsenic  and  ATRA-induced  reactive  oxygen 
species production, cytotoxicity and maturation of 
APL cells (18, 20). Condino-Neto et al (21) have 
shown that Dex down-regulates the components of 
NADPH oxidase and their activities. Therefore one 
can translate the suppressive effect of Dex on the 
apoptotic effects of ATO and ATRA to the decrease 
in the activity of NADPH oxidase.
Taken  together,  results  of  this  study  showed 
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